Breast Cancer

Data indicate an adjuvant chemotherapy has low risk of cardiotoxicity

Published in Gene Therapy Weekly, August 26th, 2004

Data published in the August 2, 2004, Journal of Clinical Oncology show that two chemotherapy regimens using different doses of epirubicin hydrochloride injection are associated with a low risk of heart damage in women with breast cancer.

This is the first sub-study to evaluate patients more than 8 years after they completed adjuvant treatment with epirubicin hydrochloride injection (brand name: Ellence; Pharmacia Corp. [now Pfizer]) and builds upon results of the FASG-05 study, which demonstrated significant 5- and 10-year disease-free and overall survival benefits in patients treated with Ellence, an anthracycline cytotoxic agent.

According...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-08-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry